Emergex completes £8.4m Series A vaccines funding
The risk posed by infectious diseases is “greater than ever before”.
Read More
Tag: Emergex
Emergex to drive vaccine development with R&D facility and new hire
Emergex has secured a ‘state-of-the-art’ research and development (R&D) facility and hired a new chief scientific officer to drive development of its vaccines.
Read More
Emergex wins Innovate UK grant to advance universal flu vaccine
A UK biotech working on a pioneering a new approach to developing vaccines for infectious diseases has been awarded a grant of £979,318 by Innovate UK.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
